Avoid exposure to sunlight; wear protective clothing and use sunscreen. Use of eye ointment may cause transient blurring of vision and other eye disturbances, if affected, do not drive or operate machinery.
Monitor renal, hepatic and haematopoietic functions periodically; mental status. Obtain CBC and temperature. Assess culture and sensitivity prior to starting therapy.
Symptoms: Nausea, vomiting, hypersensitivity. Crystalluria and haematuria may occur following very large dose. Management: Symptomatic and supportive treatment. Oral fluids may be given in case of severe vomiting and diarrhoea.
Absorption may be impaired by divalent and trivalent cations (e.g. Al, Ca, Mg, Fe, Zn), Na bicarbonate, bismuth subsalicylate, kaolin-pectin, sucralfate, colestipol and colestyramine. May form a complex with strontium ranelate, resulting in decreased absorption of tetracycline. May interfere with the bactericidal action of penicillin. May prolong the effect of anticoagulants. May reduce plasma-atovaquone concentration. May decrease the efficacy of oral contraceptives. Nephrotoxic effects may be exacerbated by diuretics or other nephrotoxic drugs. May increase the hypoglycaemic effect of insulin and sulfonylureas in patients with diabetes mellitus. May increase the toxic effects of ergot alkaloids and methotrexate. May increase lithium and digoxin levels. May diminish therapeutic effects of BCG, BCG vaccine, typhoid vaccine. Potentially Fatal: Increased risk of benign intracranial hypertension when given concurrently with retinoids (e.g. acitretin, tretinoin, isotretinoin). Concurrent use of methoxyflurane may result in renal toxicity.
Absorption may be impaired by food, milk or milk products.
May interfere with diagnostic tests including determination of urinary catecholamines or glucose.
Description: Tetracycline exhibits its bacteriostatic action by reversibly binding to the 30S subunits of the ribosome, thereby preventing the binding of aminoacyl transfer RNA and inhibiting protein synthesis, thus arresting cell growth. Pharmacokinetics: Absorption: Incompletely absorbed from the gastrointestinal tract. Bioavailability: Approx 60-80%. Time to peak plasma concentration: Approx 1-4 hours. Distribution: Widely distributed in body tissues and fluids e.g. ascitic, synovial and pleural fluids. Crosses the placenta and enters breast milk. Plasma protein binding: 55-64%. Excretion: Via urine (up to 55% as unchanged drug) and faeces. Elimination half-life: 8 hours (range: 6-12 hours).
S01AA09 - tetracycline ; Belongs to the class of antibiotics. Used in the treatment of eye infections. J01AA07 - tetracycline ; Belongs to the class of tetracyclines. Used in the systemic treatment of infections. D06AA04 - tetracycline ; Belongs to the class of topical tetracycline and derivatives agents used in the treatment of dermatological diseases.
Anon. Tetracycline (Systemic). Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 01/10/2019 .Buckingham R (ed). Tetracycline. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 01/10/2019 .Tetracycline 3% First Aid Antibiotic Ointment (Sample Solutions, LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 01/10/2019 .Tetracycline Hydrochloride Capsule (Actavis Pharma, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 01/10/2019 .